Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to “Hold”

Ventyx Biosciences (NASDAQ:VTYX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Ventyx Biosciences Trading Up 19.1%

NASDAQ:VTYX opened at $2.81 on Friday. The stock has a market cap of $199.96 million, a P/E ratio of -1.67 and a beta of 0.97. The stock’s 50-day moving average is $2.55 and its 200-day moving average is $1.82. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.07. As a group, equities analysts forecast that Ventyx Biosciences will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Ventyx Biosciences by 376.4% in the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company’s stock worth $9,359,000 after acquiring an additional 3,376,446 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Ventyx Biosciences by 15.9% during the 4th quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock worth $4,380,000 after buying an additional 275,000 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Ventyx Biosciences during the 4th quarter worth approximately $3,903,000. Redmile Group LLC boosted its holdings in shares of Ventyx Biosciences by 1,164.1% during the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock worth $1,805,000 after buying an additional 1,445,615 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Ventyx Biosciences by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company’s stock worth $3,095,000 after buying an additional 21,337 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.